CBM Biotechnology (Shanghai) Co., Ltd., a subsidiary of CBM Biotechnology Group, is a diversified cell therapy biomedical product research and development platform, and is committed to the development of therapeutic products for cancer and degenerative diseases
Cellular Biomedicine Group (NASDAQ: CBMG) was officially listed on the NASDAQ in 2014, becoming the only Chinese cell therapy biotechnology company listed on the NASDAQ. With keen industry perception, accurate judgment and strong R&D strength, CBM has taken the lead in building an internationally leading diversified cell therapy biomedical product R&D platform, developing immune cell therapy products for the treatment of cancer and stem cell therapy products for the treatment of degenerative diseases.
The tumor immune cell therapy platform covers chimeric antigen receptor T cell technology (CAR-T) and tumor therapeutic vaccine technology (GVAX vaccine Dendristim™) for the development of cell therapy products for the treatment of solid tumors such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma and advanced lung cancer. Sibilman cooperated with the General Hospital of the People's Liberation Army of Chinese People's Liberation Army (301 Hospital) to carry out clinical research on chimeric receptor T cells (CAR-T) for the treatment of hematologic tumors and solid tumors, and a number of clinical research results have aroused great attention from the international academic community, marking that China has become one of the international leaders in tumor immunotherapy research. CBM has initiated a Phase I clinical study of CD19-targeting CAR-T technology in refractory diffuse large B-cell lymphoma (DLBCL). The technology is optimized and improved on the basis of CBM-C19.1, the patented CAR-T patent of CBM-T, and is prepared at its own GMP production center.
The stem cell platform covers the development of products for the treatment of degenerative diseases such as knee osteoarthritis and cartilage damage. Among them, the data from the phase II clinical study of autologous adipose stem cell technology (ReJoin®) for the treatment of degenerative knee osteoarthritis have been the clinical results of successfully altering osteoarthritis. AlloJoinTM has entered the phase I clinical study of allogeneic adifa-derived mesenchymal stem cells (AlloJoinTM) for the treatment of knee osteoarthritis, which is the first clinical attempt by CBM to transform allogeneic adipo-derived mesenchymal stem cells from an individualized clinical treatment model to a universal type (Off-the-Shelf, OTS), with the aim of developing and producing more mature and convenient stem cell products for the treatment of knee osteoarthritis.
CBM has nearly 80 world-leading stem cell and immune cell technology patents (including granted and pending), including 13 international patents and 10 PCT patents. CBM's chimeric antigen receptor (CART-CD20) technology for the treatment of malignant tumors has been granted a patent by the Chinese Patent Office, becoming the first CD20-targeted immune cell therapy technology for malignant tumors in China to obtain a national patent.
CBM has GMP production facilities in China that meet the US FDA standards and Chinese national standards, distributed in Shanghai, Beijing and Wuxi, with a total area of more than 3,000 square meters and 12 independent production lines, and is also one of the few cell therapy technology companies in China that has been certified by international SGS to meet the ISO9001 quality system, with clinical-grade and standardized cell preparation processes and supporting technologies, and more than 1,000 standard management documents (SMP) and standard operating procedures (SOPs). The company has cell banks in multiple cities, which can store more than 200,000 cells of individual origin, and has the most advanced cold chain temperature control system (IT cloud system) to monitor cell culture, storage and transportation.
Adhering to the concept of "saving lives and rejuvenating lives", the company has brought together a large number of outstanding stem cell and immunotherapy technical talents and management teams, through the development and introduction of the world's most advanced biological therapy technology, and the cooperation with scientific research and innovation platforms such as the world's largest research hospitals and scientific research institutions, to build a solid translational medicine platform in an all-round way, and strive to become the world's leading Chinese innovative cell biomedical technology company, providing the safest and most effective immunotherapy technology and products for patients around the world.
